ADIA Med Nearly Doubles Nine-Month Revenue to Surpass $1 Million
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADIA Med (ADIA) reported nine-month revenue above $1 million, with growth in medical procedures and higher third-quarter revenue. Revenue for the nine months ended September 30, 2026 rose approximately 95% to $1,019,245; third-quarter revenue increased approximately 37% to $454,385. Gross profit reached $474,338 for nine months and $220,981 for the quarter.
On September 30, ADIA sold a 30% interest in Adia Labs to Live Oak Health, doing business as QCM Biologics, for $1,500,000: $1,000,000 cash and a $500,000 promissory note. ADIA retained majority ownership. Quarter-end cash was $1,137,818, assets were $2,452,987 and equity was $970,404. After quarter end, it fully repaid its CEO-provided revolving credit facility. Third-quarter results swung to a $53,015 net loss from $70,376 net income; the nine-month loss widened to $271,922 from $169,839. The company expects continued platform investment as it works toward profitability.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointNine-month revenue rose approximately 95% to $1,019,245, from $521,958 in the comparable 2025 period.
- Moderate pointNine-month gross profit grew to $474,338, from $243,461 in the comparable 2025 period.
- Moderate pointAdia Labs interest sale brought $1,000,000 cash and a $500,000 promissory note; ADIA retained majority ownership.
- Moderate pointCEO-provided unsecured revolving credit facility was fully repaid and discharged after quarter end.
- Minor pointThird-quarter revenue increased approximately 37% to $454,385, from $332,048 a year earlier.
3 minor points
- Minor pointThird-quarter gross profit increased to $220,981, from $203,485 in the prior-year quarter.
- Minor pointNine-month medical procedure revenue more than doubled year over year.
- Minor point. Forward-looking: it has not happened yet and may not happen.ADIA expects continued investment in its medical and biologics platform while working toward profitability.
Negative
- Moderate pointThird-quarter results shifted to a $53,015 net loss from $70,376 net income in 2025.
- Minor pointNine-month net loss widened to $271,922, compared with $169,839 a year earlier.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Third-quarter revenue up
Winter Park, Florida--(Newsfile Corp. - November 17, 2026) - ADIA Med, Inc. (OTCQB: ADIA) today announced that revenue for the nine months ended September 30, 2026 rose approximately
"Medical procedure revenue more than doubled year-over-year in the first nine months, and the Adia Labs transaction strengthened our balance sheet while we continue to scale operations," said Larry Powalisz, Chief Executive Officer of ADIA Med. "We remain focused on building our platform and working toward profitability."
Financial and Operational Highlights
- Third-quarter revenue increased approximately
37% to$454,385 , from$332,048 a year earlier. - Third-quarter gross profit grew to
$220,981 , from$203,485 in the prior-year quarter. - Nine-month gross profit nearly doubled to
$474,338 , from$243,461 in the comparable 2025 period. - Cash stood at
$1,137,818 at September 30, 2026, with total assets of$2,452,987 and stockholders' equity of$970,404 . - Strategic partnership: On September 30, ADIA Med sold a
30% membership interest in Adia Labs LLC to Live Oak Health LLC (d/b/a QCM Biologics) for$1,500,000 ($1,000,000 cash and a$500,000 promissory note), strengthening the balance sheet while retaining majority ownership. - Line of credit repaid: After quarter end, the Company fully repaid and discharged its unsecured revolving line of credit facility with its Chief Executive Officer.
Net Results
For the third quarter, the Company reported a net loss of
Form 10-Q: The Company's Quarterly Report on Form 10-Q for the period ended September 30, 2026 is available at: View ADIA Med's Third Quarter 2026 Form 10-Q
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.
About Adia Med Inc.
Adia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a regenerative medicine company built around active, IRB-approved stem cell therapy studies. Through its Adia Med clinics, the company delivers stem cell treatments alongside complementary services like platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies, The current studies are targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned for 2026. Its Adia Labs division manufactures regenerative products (AdiaVita, AdiaLink) that supply this clinical work.
Adia Labs generates revenue by manufacturing and selling regenerative products (AdiaVita and AdiaLink) to Adia Med clinics and external providers. Adia Med clinics generate revenue through patient treatments (stem cell therapies, PRP, TPE, and aHSCT). Additional revenue comes from the company's
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @adia_med
Instagram: @adia_med
Facebook: @adia_med
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324337
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
